Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

被引：0
|
作者：
Edward Sausville
Patricia LoRusso
Michael Carducci
Judith Carter
Mary F. Quinn
Lisa Malburg
Nilofer Azad
David Cosgrove
Richard Knight
Peter Barker
Sonya Zabludoff
Felix Agbo
Patricia Oakes
Adrian Senderowicz
机构：
[1] University of Maryland,Marlene and Stewart Greenebaum Cancer Center
[2] Wayne State University School of Medicine,Karmanos Cancer Center
[3] Johns Hopkins Medical Institutions,Sidney Kimmel Comprehensive Cancer Center
[4] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
AZD7762; Chk1; Solid tumors; Phase I; Safety; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：539 / 549
页数：10
相关论文
共 50 条
  • [31] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [32] A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Leong, Stephen
    Moss, Rebecca A.
    Bowles, Daniel W.
    Ware, Joseph A.
    Zhou, Jing
    Spoerke, Jill M.
    Lackner, Mark R.
    Shankar, Geetha
    Schutzman, Jennifer L.
    van der Noll, Ruud
    Voest, Emile E.
    Schellens, Jan H. M.
    ONCOLOGIST, 2017, 22 (12): : 1491 - 1499
  • [33] Phase I dose-escalation study of ON 01910. Na in combination with oxaliplatin in patients with advanced solid tumors
    Chaudhary, I.
    Rajdev, L.
    Swami, U.
    Wilhelm, F.
    Cohen, B.
    Haigentz, M.
    Kaubisch, A.
    Goel, S.
    Mani, S.
    Ghalib, M. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
    Rixe, Olivier
    Puzanov, Igor
    LoRusso, Patricia M.
    Cohen, Roger B.
    Morris, John C.
    Olowokure, Olugbenga O.
    Yin, Jian Y.
    Doroumian, Severine
    Shen, Liji
    Olszanski, Anthony J.
    ANTI-CANCER DRUGS, 2015, 26 (07) : 785 - 792
  • [35] Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors
    Nemunaitis, J. J.
    Senzer, N. N.
    Kurzrock, R.
    Ng, C. S.
    Das, A.
    Atienza, R. S.
    Zang, E. A.
    Jansen, M.
    Ashworth, S.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
    Díaz-Rubio, E
    Evans, TRJ
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Bisset, D
    Regueiro, P
    Baselga, J
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 558 - 565
  • [37] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Véronique Diéras
    Thomas Bachelot
    Mario Campone
    Nicolas Isambert
    Florence Joly
    Christophe Le Tourneau
    Philippe Cassier
    Emmanuelle Bompas
    Pierre Fumoleau
    Sabine Noal
    Christine Orsini
    Marta Jimenez
    Diane Charlotte Imbs
    Etienne Chatelut
    Oncology and Therapy, 2016, 4 (2) : 211 - 223
  • [38] Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors
    Bendell, JC
    Eder, JP
    Clark, JW
    Fidias, P
    Lynch, TJ
    Seiden, MV
    Ryan, DP
    CANCER, 2005, 103 (09) : 1925 - 1931
  • [39] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Dieras, Veronique
    Bachelot, Thomas
    Campone, Mario
    Isambert, Nicolas
    Joly, Florence
    Le Tourneau, Christophe
    Cassier, Philippe
    Bompas, Emmanuelle
    Fumoleau, Pierre
    Noal, Sabine
    Orsini, Christine
    Jimenez, Marta
    Imbs, Diane Charlotte
    Chatelut, Etienne
    ONCOLOGY AND THERAPY, 2016, 4 (02) : 211 - 223
  • [40] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
12345